company background image
5300

Jubilant Pharmova BSE:530019 Stock Report

Last Price

₹412.50

Market Cap

₹65.7b

7D

2.4%

1Y

-50.5%

Updated

18 May, 2022

Data

Company Financials +
530019 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance2/6
Financial Health5/6
Dividends5/6

530019 Stock Overview

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide.

Jubilant Pharmova Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jubilant Pharmova
Historical stock prices
Current Share Price₹412.50
52 Week High₹925.00
52 Week Low₹384.85
Beta2.15
1 Month Change-10.59%
3 Month Change-6.07%
1 Year Change-50.54%
3 Year Change-20.65%
5 Year Change-42.95%
Change since IPO1,746.16%

Recent News & Updates

Shareholder Returns

530019IN PharmaceuticalsIN Market
7D2.4%3.1%1.7%
1Y-50.5%-10.9%10.5%

Return vs Industry: 530019 underperformed the Indian Pharmaceuticals industry which returned -10.4% over the past year.

Return vs Market: 530019 underperformed the Indian Market which returned 10.6% over the past year.

Price Volatility

Is 530019's price volatile compared to industry and market?
530019 volatility
530019 Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement7.3%
10% most volatile stocks in IN Market10.0%
10% least volatile stocks in IN Market4.8%

Stable Share Price: 530019 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 530019's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19786,000Hari Shanker Bhartiahttps://www.jubilantpharmova.com

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States.

Jubilant Pharmova Fundamentals Summary

How do Jubilant Pharmova's earnings and revenue compare to its market cap?
530019 fundamental statistics
Market Cap₹65.67b
Earnings (TTM)₹5.27b
Revenue (TTM)₹61.82b

12.5x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
530019 income statement (TTM)
Revenue₹61.82b
Cost of Revenue₹14.62b
Gross Profit₹47.20b
Other Expenses₹41.93b
Earnings₹5.27b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 20, 2022

Earnings per share (EPS)33.12
Gross Margin76.35%
Net Profit Margin8.53%
Debt/Equity Ratio57.8%

How did 530019 perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

15%

Payout Ratio

Valuation

Is Jubilant Pharmova undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


18.4%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 530019 (₹412.5) is trading below our estimate of fair value (₹505.81)

Significantly Below Fair Value: 530019 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 530019 is good value based on its PE Ratio (12.5x) compared to the Indian Pharmaceuticals industry average (21.4x).

PE vs Market: 530019 is good value based on its PE Ratio (12.5x) compared to the Indian market (20.6x).


Price to Earnings Growth Ratio

PEG Ratio: 530019 is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: 530019 is good value based on its PB Ratio (1.3x) compared to the IN Pharmaceuticals industry average (2.6x).


Future Growth

How is Jubilant Pharmova forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


20.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 530019's forecast earnings growth (20.4% per year) is above the savings rate (6.7%).

Earnings vs Market: 530019's earnings (20.4% per year) are forecast to grow faster than the Indian market (18.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 530019's revenue (7.8% per year) is forecast to grow slower than the Indian market (11.9% per year).

High Growth Revenue: 530019's revenue (7.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 530019's Return on Equity is forecast to be low in 3 years time (10.9%).


Past Performance

How has Jubilant Pharmova performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


3.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 530019 has high quality earnings.

Growing Profit Margin: 530019's current net profit margins (8.5%) are lower than last year (9%).


Past Earnings Growth Analysis

Earnings Trend: 530019's earnings have grown by 3.4% per year over the past 5 years.

Accelerating Growth: 530019's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 530019 had negative earnings growth (-36.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.5%).


Return on Equity

High ROE: 530019's Return on Equity (10.3%) is considered low.


Financial Health

How is Jubilant Pharmova's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 530019's short term assets (₹32.6B) exceed its short term liabilities (₹11.6B).

Long Term Liabilities: 530019's short term assets (₹32.6B) exceed its long term liabilities (₹32.1B).


Debt to Equity History and Analysis

Debt Level: 530019's net debt to equity ratio (40.9%) is considered high.

Reducing Debt: 530019's debt to equity ratio has reduced from 112.3% to 57.8% over the past 5 years.

Debt Coverage: 530019's debt is well covered by operating cash flow (54.3%).

Interest Coverage: 530019's interest payments on its debt are well covered by EBIT (7.8x coverage).


Balance Sheet


Dividend

What is Jubilant Pharmova current dividend yield, its reliability and sustainability?

Dividend Score

5/6

Dividend Score 5/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.21%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 530019's dividend (1.21%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).

High Dividend: 530019's dividend (1.21%) is low compared to the top 25% of dividend payers in the Indian market (1.58%).


Stability and Growth of Payments

Stable Dividend: 530019's dividends per share have been stable in the past 10 years.

Growing Dividend: 530019's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (15.1%), 530019's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (7.8%), 530019's dividend payments are thoroughly covered by cash flows.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.9yrs

Average management tenure


CEO

Hari Shanker Bhartia (65 yo)

40.33yrs

Tenure

₹121,803,665

Compensation

Mr. Hari Shanker Bhartia, B.E., B.Tech, serves as Non-Executive Director at DP Eurasia N.V. since April 21, 2021. He serves as the Non-Executive Independent Director of Shriram Pistons & Rings Limited sinc...


CEO Compensation Analysis

Compensation vs Market: Hari Shanker's total compensation ($USD1.57M) is above average for companies of similar size in the Indian market ($USD338.05K).

Compensation vs Earnings: Hari Shanker's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 530019's management team is seasoned and experienced (7.9 years average tenure).


Board Members

Experienced Board: 530019's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Jubilant Pharmova Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Jubilant Pharmova Limited
  • Ticker: 530019
  • Exchange: BSE
  • Founded: 1978
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹65.672b
  • Shares outstanding: 159.21m
  • Website: https://www.jubilantpharmova.com

Number of Employees


Location

  • Jubilant Pharmova Limited
  • 1A, Sector 16A
  • Noida
  • Uttar Pradesh
  • 201301
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/18 00:00
End of Day Share Price2022/05/18 00:00
Earnings2021/12/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.